University of Manchester spin-out co-founder voted the Most Influential Thinker in HR

Written by UMIP on . Posted in News

University of Manchester spin-out co-founder Professor Sir Cary Cooper of Robertson Cooper Ltd has been voted the Most Influential Thinker in HR 2014, in a new poll of UK HR Directors for HR Magazine.

The award, nominated by all members of the HR community in UK business, recognises Cary’s contribution, working with businesses in the field of health and wellbeing, as Founder of wellbeing experts Robertson Cooper and as Professor of Organisational Health and Psychology at Lancaster University.

Voted at number 2 in 2013, Cary has risen to the top spot, holding off Peter Cheese, the CEO of the Chartered Institute of Personnel and Development.

Professor Sir Cary was knighted this year for services to social sciences and has previously filled many roles including Lead Scientist on the Foresight Review of Mental Capital and Well-Being and Chair of the Global Agenda Council on Chronic Disease of the World Economic Forum. He is currently the Chair of the Academy of Social Sciences and President of RELATE.

Professor Sir Cary comments: “It is a great honour to be considered by the leading HR Directors in the UK as an important HR thought leader, and an acceptance of the importance of health and wellbeing in British business.”

Clive Rowland, CEO of UMI3 Ltd, The University of Manchester’s innovation company, comments:” The University is active in intellectual property commercialisation and knowledge transfer work across the whole campus, not only in so-called ‘high-tech’ fields, and Robertson Cooper is a successful world-leading example of this. I am delighted that Sir Cary has been recognised in this way and it is well deserved recognition for both the very hard work and the highly positive commitment that he gives to his profession.”

Find out more about Robertson Cooper at

Twitter: @gooddayatwork

F2G Limited announces a major funding award from the Technology Strategy Board’s Biomedical Catalyst

Written by UMIP on . Posted in News

The prestigious £1.4 million award will expedite the development of F2G’s novel IV/oral systemic antifungal F901318. The Biomedical Catalyst project will focus on the oral Phase I clinical development of F901318 and supporting studies, and will allow the company to accelerate its clinical development activities.

F901318 is being developed by F2G as an IV and oral therapy to treat invasive aspergillosis and other life- threatening fungal infections and is a new class of antifungal acting against a new cellular target. The discovery and development of F901318 represents a major advance in the treatment of serious fungal disease as currently there are very limited treatment options and resistance is becoming a serious problem. F901318 is highly active against all known azole-resistant aspergilli.

F2G Limited today announces commencement of a Phase 1 single ascending dose study of a novel antifungal agent

Written by UMIP on . Posted in News

F2G Limited, the antifungal research and development company today announced a major milestone in the development of its novel IV/ oral systemic antifungal (F901318) with the commencement of a Phase I clinical study. This study initiates the IV Phase I clinical development of F901318 with the oral programme expected to commence in the near future.

F901318 is being developed by F2G to treat invasive aspergillosis and other life-threatening fungal infections and is of a novel class of antifungals acting against a new cellular target. The discovery and development of F901318 represents a major advance in the treatment of serious fungal disease as currently there are very limited treatment options and resistance to existing drugs is becoming a serious problem. F901318 is highly active against all known azole-resistant aspergilli.

University of Manchester spin-out Spectromics Limited launches new website

Written by UMIP on . Posted in News

University of Manchester spin-out, Spectromics Limited, a medical diagnostic company providing a smarter way to tackle antibiotic resistance, using its rapid point-of-prescription test, has just launched its new website at

One of the major causes of antibiotic resistance is that patients are treated without the use of diagnostics to guide treatment today. To-date this has been the case because the tests required to determine resistance or susceptibility of a panel of antibiotics has taken days to perform in a laboratory, distant from the point-of- prescription. This empirical issuing of antibiotics results in giving patients antibiotics when they don’t have a bacterial infection, or an antibiotic that the infection is resistant to, both these actions allow bacteria to build further resistance.

The Spectromic solution is a 10 minute test that fits within a doctor / patient appointment and the test determines whether a bacterial infection is present, and if so which antibiotic/s will most effectively treat the particular infection.

Despite the rising incidence of antibiotic resistance, we still have a large number of antibiotics to use against infections, using these drugs effectively will reduce the escalation in resistance, and allow us to conserve last-line antibiotics.

The first test that Spectromics is developing is for urinary tract infection, the largest bacterial infection in man that accounts for 15% of all community prescribed antibiotics. The test is being designed to be simple to use by untrained staff as it’s expected to be predominantly carried out in primary care settings. However it will also have utility in institutional settings as in the US some 30% of UTI cases present at ER units due to patients feeling unwell and with a fever. By triaging patients in ER settings for UTI early the patient treatment costs associated with such infections in ER settings can be largely avoided (ER costs are 10x higher than in primary care according to a study carried out by the Henry Ford Hospital, Detroit last year).

Contact Spectromics: email  tel +44 (0)1580 891106.

Follow Spectromics on Twitter: @Spectromics


Written by UMIP on . Posted in News

Morgan Advanced Materials has announced a new joint development agreement with The University of Manchester, aimed at scaling up a new process for manufacturing graphene – a one-atom thick carbon allotrope first isolated at the university ten years ago and for which two Nobel Prizes were awarded.

The world’s thinnest material and a potent conductor, graphene is also extremely lightweight, chemically inert and has a large surface area which means, with further research and testing, it could change the way we think about electrical and chemical engineering.

Bringing together some of the University’s leading graphene researchers and Morgan’s 150 years of carbon processing expertise, the partnership will explore the full potential of graphene, with a particular interest in understanding and optimising the relationship between the manufacturing process and materials science. The partnership has been established to improve the prospects of bringing this material to commercial reality. Morgan initially began work with The University of Manchester in early 2010 on a number of Government-funded materials and related programmes, and the joint graphene development agreement represents the next stage in this relationship.

The University of Manchester, the home of graphene, was where the scientific discovery was made. It has around 200 graphene researchers and is a world leader in applied and fundamental graphene research. The £61m National Graphene Institute at the University is set to open in early 2015, funded by £38m from the Engineering and Physical Sciences Research Council and £23m from the European Regional Development Fund. The integrated Morgan and University academic team will therefore be working within a significant community of graphene expertise and facilities.

Dr Mike Murray, Chief Technology Officer of Morgan Advanced Materials commented: “With decades of expertise in developing specialist carbon-based materials, Morgan’s material scientists will be based full time at the university, working closely with academic colleagues to understand the manufacturing mechanism and properties of graphene, helping us explore the applications where the technology can be used for optimum benefit.”

Clive Rowland, CEO of the University’s Innovation Company, UMI3, added: “To explore and fully exploit the properties of graphene, commercial partnerships are vital. I am very pleased with our collaboration with Morgan, which is based around an intellectual property project that we have taken to the proof-of-principle stage. We have consistently said that joining forces with world-class companies like Morgan Advanced Materials and tapping into such engineering and industrial experience will help us realise the full potential of the material and greatly assist us in overcoming the myriad challenges of taking an entirely new material from the laboratory all the way through to the manufacturing stage and ultimately to market adoption of industrial products and perhaps consumer products in due course.”

For more information on graphene visit


Privacy Policy / Terms and Conditions / © Copyright 2014 The University of Manchester Intellectual Property / Created by HTP Digital

The University of Manchester Intellectual Property ("UMIP") acts solely as agent for the University in relation to any matter relating to intellectual property ("IP") and know how created at the University. This is whether such IP is created by employees, students or others. UMIP does not represent anyone else in such matters. If anyone else requires advice in relation to such IP then they must take their own independent legal advice.